From: Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
 | SEB-IgE(+) n = 4 | SEB-IgE(−) n = 4 | p value |
---|---|---|---|
positive number with favours mepolizumab, n(%) | 1 (25) | 4 (100) | 0.14a |
ECRS as comorbidity, n(%) | 2 (50) | 4 (100) | 0.43a |
change from baseline in ACT score(pts) | 4.5 (7.0) | 3.8 (3.0) | 0.77b |
change from baseline in OCS dosec(%) | −4.8 (8.2) | −64 (41) | 0.046b |
change from baseline in exacerbation(%) | −8.8 (98) | −77 (42) | 0.24b |